Drug interactions
Obinutuzumab + Poliovirus vaccine inactivated
Severity: Moderate
Obinutuzumab and Poliovirus vaccine inactivated: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
B-cell depletion from obinutuzumab substantially weakens antibody responses to inactivated polio vaccine. Patients may not achieve protective immunity.
What this interaction means in plain words
Obinutuzumab and Poliovirus vaccine inactivated can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Obinutuzumab-induced B-cell depletion impairs humoral response to vaccination.
What to do
Give the vaccine at least 2 to 4 weeks before obinutuzumab if feasible. Otherwise revaccinate after B-cell recovery, around 6 months after therapy.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Obinutuzumab and Poliovirus vaccine inactivated, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Obinutuzumab
Frequently asked questions
Can I take Obinutuzumab with Poliovirus vaccine inactivated?
MediHelp rates the interaction as moderate. Obinutuzumab and Poliovirus vaccine inactivated can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. B-cell depletion from obinutuzumab substantially weakens antibody responses to inactivated polio vaccine. Patients may not achieve protective immunity.
How serious is the interaction between Obinutuzumab and Poliovirus vaccine inactivated?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Give the vaccine at least 2 to 4 weeks before obinutuzumab if feasible. Otherwise revaccinate after B-cell recovery, around 6 months after therapy.
What other medicines interact with Obinutuzumab?
MediHelp also lists interactions of Obinutuzumab with, for example, Measles mumps and rubella vaccine, Adenovirus types 4 and 7 live, Axicabtagene ciloleucel. The full list is on the Obinutuzumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
